Strategies for enhancing specificity and efficacy of oncolytic viruses in cancer treatment
Clinical Immunology · 2026-06 · 285 · 110708
DOI: 10.1016/j.clim.2026.110708 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Immunology, 2026-06. Verfasst von Khakimov Murod und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Faculty and Hospital Surgery, Tashkent State Medical University, Tashkent, Uzbekistan. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Neoplasms, Oncolytic Viruses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
Oncolytic viruses (OVs) are designed to selectively infect, proliferate within, and destroy cancer cells while concurrently eliciting robust antitumor immune responses. Notwithstanding their significant potential, inadequate tumor selectivity and restricted treatment efficacy persist as substantial barriers to wider clinical utilization. This review rigorously evaluates current advancements in OV engineering designed to address these issues. Transcriptional targeting, which employs tumor-specific promoters like hTERT, E2F1, and hypoxia-inducible elements, microRNA detargeting, and the redirection of viral entry towards tumor-associated antigens such as EGFR, HER2, and EpCAM, alongside multi-layered logic-gated regulatory systems, represent strategies to augment tumor specificity. To bolster anticancer efficacy, OVs have been modified with immunomodulatory agents, including cytokines (GM-CSF, IL-12), immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4), chemokines, and stroma-degrading enzymes (hyaluronidase, relaxin). Subsequent advancements encompass nanoparticle encapsulation, carrier-cell transport mechanisms, metabolic reprogramming strategies, and synergistic combinations with immunotherapy, chemotherapy, or radiotherapy. Furthermore, systems and synthetic biology techniques are enabling the development of advanced "smart" OVs, which possess the capacity for real-time detection and adaptation within the tumor microenvironment. These combined methodologies present considerable promise for enhancing the safety profile, intratumoral distribution, and overall therapeutic efficacy of oncolytic virotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Faculty and Hospital Surgery, Tashkent State Medical University, Tashkent, Uzbekistan.
- Department of Propaedeutics of Internal Diseases, Samarkand State Medical University, Samarkand, Uzbekistan.
- Department of biology, Urgench State University, Urgench, Uzbekistan.
- Department of Surgical Dentistry, Bukhara State Medical Institute Named After Abu Ali Ibn Sino, Bukhara, Uzbekistan.
- Department of Medicine, Termez University of Economics and Service, Termez, Uzbekistan.
- Department of Technological Education, Bukhara State Pedagogical Institute, Uzbekistan.
Zitieren
APA
Murod, K., Saodat, Y., Avazmetova, I., Zokir, R., Khalbayeva, Z., Nozima, K., Yo'ldashevich, J. K., Alkhawaja, A. S., & Siahmansouri, H. (2026). Strategies for enhancing specificity and efficacy of oncolytic viruses in cancer treatment. Clinical Immunology, 285, 110708. https://doi.org/10.1016/j.clim.2026.110708
Vancouver
Murod K, Saodat Y, Avazmetova I, Zokir R, Khalbayeva Z, Nozima K, et al. Strategies for enhancing specificity and efficacy of oncolytic viruses in cancer treatment. Clinical Immunology. 2026;285:110708. doi:10.1016/j.clim.2026.110708
BibTeX
@article{Murod2026,
author = {Murod, Khakimov and Saodat, Yarmukhamedova and Avazmetova, Intizor and Zokir, Raximov and Khalbayeva, Zarina and Nozima, Khamdamova and Yo'ldashevich, Jumaniyozov Kuvondik and Alkhawaja, Ali Sameer and Siahmansouri, Homayoon},
title = {Strategies for enhancing specificity and efficacy of oncolytic viruses in cancer treatment},
journal = {Clinical Immunology},
year = {2026},
volume = {285},
pages = {110708},
doi = {10.1016/j.clim.2026.110708}
}
EUVIMED